Frank Stokes - Castle Biosciences CFO Treasurer
| CSTL Stock | USD 22.84 1.49 6.12% |
CFO
Mr. Frank Stokes is Chief Financial Officer of the Company. Frank Stokes has more than 20 years of experience in finance, including extensive experience leading capital formation for highgrowth healthcare and life science companies. Most recently he was CFO of Hammock Pharmaceuticals where he assisted in the initial capitalization of the company as well as the acquisition of Hammocks foundational drug delivery technology. Previously Frank served as a Senior Investment Banker at Leerink Partners, Robert W. Baird, and Wachovia Securities . He received a B.S. in business administration followed by MBA and J.D. degrees from the University of North Carolina at Chapel Hill.
| Age | 53 |
| Professional Marks | MBA |
| Address | 505 South Friendswood Drive, Friendswood, TX, United States, 77546 |
| Phone | 866 788 9007 |
| Web | https://castlebiosciences.com |
Frank Stokes Latest Insider Activity
Tracking and analyzing the buying and selling activities of Frank Stokes against Castle Biosciences stock is an integral part of due diligence when investing in Castle Biosciences. Frank Stokes insider activity provides valuable insight into whether Castle Biosciences is net buyers or sellers over its current business cycle. Note, Castle Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Castle Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Frank Stokes over a year ago Exercise or conversion by Frank Stokes of 4000 shares of Castle Biosciences subject to Rule 16b-3 |
Castle Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.0592) % which means that it has lost $0.0592 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0782) %, meaning that it created substantial loss on money invested by shareholders. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.17. The value of Return On Capital Employed is expected to slide to -0.17. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 1.5 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M.Similar Executives
| Found 14 records | CFO Age | ||
| DEREK BERTOCCI | Guardant Health | N/A | |
| Georg Mueller | Burning Rock BiotechLtd | N/A | |
| Charles Constanti | Caredx Inc | 51 | |
| Robin Cowie | BiodesixInc | 44 | |
| Stephen Furlong | Neuronetics | 54 | |
| Herman Rosenman | Natera Inc | 70 | |
| Mark Bausinger | Neuronetics | N/A | |
| Abhishek Jain | Caredx Inc | 47 | |
| Kenneth Ludlum | Caredx Inc | 60 | |
| Ken Ludlum | Caredx Inc | 61 | |
| Michael Bell | Caredx Inc | 49 | |
| MBA MS | Exagen Inc | 45 | |
| Michael Brophy | Natera Inc | 38 | |
| Errol Farr | Burning Rock BiotechLtd | N/A | |
Management Performance
| Return On Equity | -0.0782 | ||||
| Return On Asset | -0.0592 |
Castle Biosciences Leadership Team
Elected by the shareholders, the Castle Biosciences' board of directors comprises two types of representatives: Castle Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Castle. The board's role is to monitor Castle Biosciences' management team and ensure that shareholders' interests are well served. Castle Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Castle Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Toby Juvenal, Vice President of Sales | ||
| Camilla Zuckero, Exec Communications | ||
| Derek Maetzold, President CEO, Founder, Director | ||
| John Abbott, VP Controller | ||
| Daniel Bradbury, Board Chairman | ||
| RN RN, Chief Officer | ||
| Kristen RN, Chief Officer | ||
| Tobin Juvenal, Chief Officer | ||
| Kevin Doman, Vice Sales | ||
| Alice Izzo, Senior Marketing | ||
| Matthew MD, Senior Medical | ||
| Keli Greenberg, VP Resources | ||
| Robert Cook, Senior Development | ||
| Kristen Oelschlager, Vice President - Operations | ||
| Frank Stokes, CFO Treasurer | ||
| Bernhard Spiess, Company Secretary |
Castle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Castle Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0782 | ||||
| Return On Asset | -0.0592 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 454.55 M | ||||
| Shares Outstanding | 27.61 M | ||||
| Shares Owned By Insiders | 3.03 % | ||||
| Shares Owned By Institutions | 89.16 % | ||||
| Number Of Shares Shorted | 1.46 M | ||||
| Price To Earning | 87.86 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Castle Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Castle Biosciences' short interest history, or implied volatility extrapolated from Castle Biosciences options trading.
Pair Trading with Castle Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Castle Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Castle Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving together with Castle Stock
| 0.69 | EDSA | Edesa Biotech Financial Report 9th of May 2024 | PairCorr |
Moving against Castle Stock
| 0.64 | INDP | Indaptus Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.57 | GBIO | Generation BioCo Financial Report 8th of May 2024 | PairCorr |
| 0.46 | LYRA | Lyra TherapeuticsInc Financial Report 10th of May 2024 | PairCorr |
| 0.41 | VTYX | Ventyx Biosciences Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Castle Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Castle Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Castle Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Castle Biosciences to buy it.
The correlation of Castle Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Castle Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Castle Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Castle Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for Castle Stock analysis
When running Castle Biosciences' price analysis, check to measure Castle Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Castle Biosciences is operating at the current time. Most of Castle Biosciences' value examination focuses on studying past and present price action to predict the probability of Castle Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Castle Biosciences' price. Additionally, you may evaluate how the addition of Castle Biosciences to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Castle Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share (1.13) | Revenue Per Share 9.279 | Quarterly Revenue Growth 0.736 | Return On Assets (0.06) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.